Tillman Gerngross is the founder of Adagio Therapeutics. Adagio Therapeutics has raised $80M in total funding. Latest round: Series B.
Tillman Gerngross is the CEO of Adagio Therapeutics, a company that develops best-in-class antibodies designed to broadly neutralize SARS-CoV-2, SARS-CoV-1, and other emergent coronaviruses. The company focuses on creating antibodies for both therapeutic and prophylactic treatments. Adagio Therapeutics successfully raised an $80 million Series B financing round in November 2020.
Full founder directory · Investor directory · Company funding database · Fundraising library